Volume-Outcome Relationship in Pancreatic SurgeryPaSuTNCT06389890
Pancreatic Surgery - Optimal Caseload Thresholds and Predictive Accuracy
An observational study of Volume-Outcome Relationship in Pancreatic Surgery, run by Richard Hunger.
Trial summary
The main objective of the study is to identify the optimal annual number of cases in a hospital with regard to minimising hospital mortality in pancreatic surgery. In particular, the prognostic value of such case numbers will be analysed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Volume-Outcome Relationship in Pancreatic Surgery
- What is being tested?
- Pancreatic resection procedure
- Type of treatment
- Surgery or procedure
- How many people
- 80,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2010to 31 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population encompasses all patients that underwent any pancreatic resection procedure in any German hospital (full survey of the German population).
Who may be able to join
- at least 18 years old
- any pancreatic resection procedure
- operated at any German hospital
Who cannot join
- any transplantation procedure
- Inpatient admission for organ removal
- no information on sex
- no information on age
About this study
The main objective of the study is to identify the optimal annual number of cases in a hospital with regard to minimising hospital mortality in pancreatic surgery. In particular, the prognostic value of such case numbers will be analysed.
Read the detailed description
Main research questions:
- Can specific intervention case numbers be identified that are suitable as thresholds for annual minimum volumes and are associated with significantly low hospital mortality?
- Almost all previous studies on case number effects have only shown a descriptive association between the number of cases in a given year and the quality of outcomes in the same year. The aim of this study is to investigate whether the correlations described can be demonstrated when using the previous year's procedure volume as a predictor. The study seeks to answer whether the procedure caseload has predictive value, specifically the number of cases in one year and in-hospital mortality in the following year.
Background:
Numerous studies have demonstrated a correlation between the number of cases and the quality of outcomes for various surgical procedures. For instance, patients who underwent surgery in high-volume hospitals (HVH) had lower mortality rates, longer survival rates, lower complication rates, and lower reoperation rates than patients who underwent surgery in low-volume hospitals (LVH). To subdivide into HVHs and LVHs, either concrete case numbers or quartile or quintile limits with an equal number of operations or clinics per group wer used. The aim of the study is to objectively determine these limits using a spline-modeled caseload term, avoiding arbitrary decisions.
One limitation of the previous findings is that they may not be generalisable due to the use of a limited number of cases and outcome quality from the same year. However, it is important to note that the volume from the previous year is crucial in determining the predictive importance of caseload for future outcome quality. A recent study (in press) reported, that there are significant fluctuations in the quality of outcomes among HVHs, even between different years. Therefore, it was hypothesized that using the number of cases as a predictor of high-quality outcomes may lead to overestimation.
Methods:
The nationwide hospital billing data for Germany (DRG statistics) for the period 2010 to 2019 will be analysed. The risk-adjusted mortality rates are determined. For this purpose, logistic regression models are calculated that adjust the mortality risk for the following variables Sex, age, emergency of admission, year of resection, diagnosis (malign neoplasm vs. benign neoplasm vs. neoplasm of unclear dignity vs. acute pancreatitis vs. chronic pancreatitis vs. other pancreatic diseases), additional procedures (venous resections/ multivisceral resections/ arterial resections/ splenectomy/ cholecystectomy/ biliary drainage/ dialysis procedures) and selected comorbidities. To classify additional procedures in order to reflect extent of surgery and technical difficulty, a slight modification of the classification system as described in Mihaljevic et al, 2021 will be used (PMID: 33386130). The Elixhauser definitions are used for the comorbidities as described in Quan et al, 2005 (PMID: 16224307). The selection of comorbidities to be considered is based on the publication by Hunger et al, 2022 (PMID: 35525416).
The case number effect is modelled using natural cubic splines. The 10th, 20th, 40th, 60th, 80th and 90th case number percentiles are used as node points. The adjusted hospital mortality as a function of the number of cases is determined using Estimated Marginal Means. Local extremes (maxima and minima) in the splines are determined using 1st and 2nd graph derivate.
Various regression models are calculated using either the number of cases from the current year of operation or the previous year. The predictive accuracy of the models is determined using the established measures from signal detection theory (AUC, sensitivity, specificity, positive predictive value, negative predictive value). Subgroup analyses for individual resection procedures will be performed.
- Being tested
- Pancreatic resection procedure
- Keywords
- Outcome Assessment, General Surgery, Pancreatic Surgery, Public Health, Hospital Planning, Centralized Hospital Services
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pancreatic resection procedureProcedure or surgery
Pancreatic resection procedure
| Study group | Role | What they receive |
|---|---|---|
| All patients undergoing pancreatic surgery | All patients with at least one pancreatic surgery procedure code Receives: Procedure: Pancreatic resection procedure | |
| Subgroup: Total pancreatectomy | All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55250', '55251', '55252', '5525x', '5525y' Receives: Procedure: Pancreatic resection procedure | |
| Subgroup: Pancreaticoduodenectomy | All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55241', '55242', '55243' Receives: Procedure: Pancreatic resection procedure | |
| Subgroup: Segmental resection | All patients with at least one of the following pancreatic procedure code (OPS-codes): '55244' Receives: Procedure: Pancreatic resection procedure | |
| Subgroup: Distal pancreatectomy | All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55240', '552400', '552401', '552402' Receives: Procedure: Pancreatic resection procedure | |
| Subgroup: Other partial resections | All patients with at least one of the following pancreatic procedure codes (OPS-codes): '5524x', '5524y' Receives: Procedure: Pancreatic resection procedure |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-hospital mortality
Patient died during or after surgery
Measured: within 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2024
- Study start1 Jan 2010
- Primary completion31 Dec 2019
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Volume-Outcome Relationship in Pancreatic SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 80,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Richard Hunger
- Sponsor type
- University, hospital or other
- Collaborators
- Medizinische Hochschule Brandenburg Theodor Fontane
- Responsible party
- Sponsor-investigator, Richard Hunger, Medizinische Hochschule Brandenburg Theodor Fontane
- Investigators
- Rene Mantke, MD, Study director, Head of Surgery at University Hospital Brandenburg an der Havel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06389890
- Sponsor's protocol ID
- PaSuTE
- Acronym
- PaSuT
- Status last verified
- Apr 2024
- First submitted
- 15 Mar 2024
- Last updated
- 29 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be analyzed by controlled remote data analysis. The data is held exclusively by the Federal Statistical Office for scientific analyses. Direct access to or data sharing of individual patient data is prohibited by German law.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pancreatic Surgery - Optimal Caseload Thresholds and Predictive Accuracy
- ClinicalTrials.gov ID
- NCT06389890
- Acronym / sponsor ID
- PaSuT / PaSuTE
- Keywords
- Outcome Assessment, General Surgery, Pancreatic Surgery, Public Health, Hospital Planning, Centralized Hospital Services
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80,000 participants (actual)
- Lead sponsor
- Richard HungerUniversity, hospital or other
- Collaborators
- Medizinische Hochschule Brandenburg Theodor Fontane
- Study start
- 1 Jan 2010 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 29 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to identify the optimal annual number of cases in a hospital with regard to minimising hospital mortality in pancreatic surgery. In particular, the prognostic value of such case numbers will be analysed.
Detailed description
Main research questions:
- Can specific intervention case numbers be identified that are suitable as thresholds for annual minimum volumes and are associated with significantly low hospital mortality?
- Almost all previous studies on case number effects have only shown a descriptive association between the number of cases in a given year and the quality of outcomes in the same year. The aim of this study is to investigate whether the correlations described can be demonstrated when using the previous year's procedure volume as a predictor. The study seeks to answer whether the procedure caseload has predictive value, specifically the number of cases in one year and in-hospital mortality in the following year.
Background:
Numerous studies have demonstrated a correlation between the number of cases and the quality of outcomes for various surgical procedures. For instance, patients who underwent surgery in high-volume hospitals (HVH) had lower mortality rates, longer survival rates, lower complication rates, and lower reoperation rates than patients who underwent surgery in low-volume hospitals (LVH). To subdivide into HVHs and LVHs, either concrete case numbers or quartile or quintile limits with an equal number of operations or clinics per group wer used. The aim of the study is to objectively determine these limits using a spline-modeled caseload term, avoiding arbitrary decisions.
One limitation of the previous findings is that they may not be generalisable due to the use of a limited number of cases and outcome quality from the same year. However, it is important to note that the volume from the previous year is crucial in determining the predictive importance of caseload for future outcome quality. A recent study (in press) reported, that there are significant fluctuations in the quality of outcomes among HVHs, even between different years. Therefore, it was hypothesized that using the number of cases as a predictor of high-quality outcomes may lead to overestimation.
Methods:
The nationwide hospital billing data for Germany (DRG statistics) for the period 2010 to 2019 will be analysed. The risk-adjusted mortality rates are determined. For this purpose, logistic regression models are calculated that adjust the mortality risk for the following variables Sex, age, emergency of admission, year of resection, diagnosis (malign neoplasm vs. benign neoplasm vs. neoplasm of unclear dignity vs. acute pancreatitis vs. chronic pancreatitis vs. other pancreatic diseases), additional procedures (venous resections/ multivisceral resections/ arterial resections/ splenectomy/ cholecystectomy/ biliary drainage/ dialysis procedures) and selected comorbidities. To classify additional procedures in order to reflect extent of surgery and technical difficulty, a slight modification of the classification system as described in Mihaljevic et al, 2021 will be used (PMID: 33386130). The Elixhauser definitions are used for the comorbidities as described in Quan et al, 2005 (PMID: 16224307). The selection of comorbidities to be considered is based on the publication by Hunger et al, 2022 (PMID: 35525416).
The case number effect is modelled using natural cubic splines. The 10th, 20th, 40th, 60th, 80th and 90th case number percentiles are used as node points. The adjusted hospital mortality as a function of the number of cases is determined using Estimated Marginal Means. Local extremes (maxima and minima) in the splines are determined using 1st and 2nd graph derivate.
Various regression models are calculated using either the number of cases from the current year of operation or the previous year. The predictive accuracy of the models is determined using the established measures from signal detection theory (AUC, sensitivity, specificity, positive predictive value, negative predictive value). Subgroup analyses for individual resection procedures will be performed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| All patients undergoing pancreatic surgery | – | Procedure: Pancreatic resection procedureAll patients with at least one pancreatic surgery procedure code |
| Subgroup: Total pancreatectomy | – | Procedure: Pancreatic resection procedureAll patients with at least one of the following pancreatic procedure codes (OPS-codes): '55250', '55251', '55252', '5525x', '5525y' |
| Subgroup: Pancreaticoduodenectomy | – | Procedure: Pancreatic resection procedureAll patients with at least one of the following pancreatic procedure codes (OPS-codes): '55241', '55242', '55243' |
| Subgroup: Segmental resection | – | Procedure: Pancreatic resection procedureAll patients with at least one of the following pancreatic procedure code (OPS-codes): '55244' |
| Subgroup: Distal pancreatectomy | – | Procedure: Pancreatic resection procedureAll patients with at least one of the following pancreatic procedure codes (OPS-codes): '55240', '552400', '552401', '552402' |
| Subgroup: Other partial resections | – | Procedure: Pancreatic resection procedureAll patients with at least one of the following pancreatic procedure codes (OPS-codes): '5524x', '5524y' |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population encompasses all patients that underwent any pancreatic resection procedure in any German hospital (full survey of the German population).
Key inclusion criteria (3 listed)
- at least 18 years old
- any pancreatic resection procedure
- operated at any German hospital
Key exclusion criteria (4 listed)
- any transplantation procedure
- Inpatient admission for organ removal
- no information on sex
- no information on age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pancreatic resection procedurePancreatic resection procedure | Procedure or surgery | All patients undergoing pancreatic surgery, Subgroup: Distal pancreatectomy, Subgroup: Other partial resections, Subgroup: Pancreaticoduodenectomy, Subgroup: Segmental resection, Subgroup: Total pancreatectomy |
Primary outcome
In-hospital mortality
Time frame: within 30 days
Patient died during or after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2024.
- Individual participant dataSharing planned: No. Data will be analyzed by controlled remote data analysis. The data is held exclusively by the Federal Statistical Office for scientific analyses. Direct access to or data sharing of individual patient data is prohibited by German law.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rene Mantke, MD study director
Head of Surgery at University Hospital Brandenburg an der Havel
Questions about this trial
What is this clinical trial studying?
An observational study of Volume-Outcome Relationship in Pancreatic Surgery, run by Richard Hunger.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-hospital mortality (time frame: within 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2024.